Abstract
Polycystic Ovary Syndrome (PCOS) is a hormonal disorder affecting women of reproductive age, often associated with oxidative stress and inflammation. This study explores the therapeutic potential of Arctium lappa phenolic-rich fraction encapsulated nanofiber (ALPRF-NF) in a testosterone-induced PCOS mouse model. All experiments were performed in triplicate and Duncan's Multiple Range Test was used to assess significant differences between means, with significance determined at p < 0.05. The ALPRF-NF formulation demonstrated favorable physicochemical properties, including a ribbon-like structure (216.9 nm), a zeta potential of -19.3 mV, and a high encapsulation efficiency (93.1%). In vivo findings showed that ALPRF-NF significantly improved body weight, feed intake, and liver enzyme profiles in PCOS-induced mice (p ≤ 0.05). It also enhanced the antioxidant defense system by elevating levels of glutathione peroxidase (GPX), superoxide dismutase (SOD), and catalase (CAT). Mechanistically, ALPRF-NF reduced oxidative stress and inflammation by delivering phenolic compounds that scavenge reactive oxygen species (ROS) and modulate gene expression in ovarian tissue. This included downregulation of inducible nitric oxide synthase (iNOS) and upregulation of SOD expression. These results suggest that ALPRF-NF effectively mitigates testosterone-induced ovarian oxidative damage and inflammation, offering a targeted, nanotechnology-based therapeutic approach for PCOS. The study provides valuable insights into novel strategies for improving women's reproductive health through bioactive compound delivery.